Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07113522 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
A Phase 2 study of Crohn's Disease and Ulcerative Colitis (UC), sponsored by Mirador Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT07113522: Recruiting Phase 2 study of Crohn's Disease and Ulcerative Colitis (UC), sponsored by Mirador Therapeutics.
NCT07113522 is a Phase 2 study of Crohn's Disease and Ulcerative Colitis (UC) that is actively recruiting participants, run by Mirador Therapeutics. The registered enrollment target is 140 participants, below the 2,393-participant average among 105 other Crohn's Disease trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07113522, a Phase 2 study of Crohn's Disease and Ulcerative Colitis (UC), is actively recruiting participants, sponsored by Mirador Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.
Conditions Studied
Interventions
- DRUG MT-201
- DRUG MT-501
Study Locations (20)
Florida
- Mirador Therapeutics Selected Site - Miami
- Mirador Therapeutics Selected Site - Miami
- Mirador Therapeutics Selected Site - Miami
- Mirador Therapeutics Selected Site - Orlando
- Mirador Therapeutics Selected Site - Palmetto Bay
- Mirador Therapeutics Selected Site - Pensacola
Louisiana
- Mirador Therapeutics Selected Site - Lafayette
- Mirador Therapeutics Selected Site - Marrero
- Mirador Therapeutics Selected Site - Shreveport
Arizona
- Mirador Therapeutics Selected Site - Scottsdale
- Mirador Therapeutics Selected Site - Sun City
Arkansas
- Mirador Therapeutics Selected Site - Little Rock
- Mirador Therapeutics Selected Site - Little Rock
Colorado
- Mirador Therapeutics Selected Site - Colorado Springs
- Mirador Therapeutics Selected Site - Littleton
Georgia
- Mirador Therapeutics Selected Site - Atlanta
- Mirador Therapeutics Selected Site - Snellville
Illinois
- Mirador Therapeutics Selected Site - Glenview
- Mirador Therapeutics Selected Site - Gurnee
Alabama
- Mirador Therapeutics Selected Site - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-06-26 |
| Est. Completion | 2028-02-04 |
| Phase | Phase 2 |
What NCT07113522 shows while recruiting
NCT07113522 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 2,393-participant average among 105 other Crohn's Disease trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which MT-201 is the first listed.
NCT07113522 names 20 study sites across 8 states, led by Florida, Louisiana, Arizona.
Frequently Asked Questions
What is clinical trial NCT07113522 about?
NCT07113522 is a clinical study titled "A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease". This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.
What is the current status of trial NCT07113522?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2025-06-26. Estimated completion is 2028-02-04.
What conditions does trial NCT07113522 study?
This clinical trial studies the following conditions: Crohn's Disease, Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD).
What interventions are being tested in trial NCT07113522?
The interventions under investigation include: MT-201 (DRUG), MT-501 (DRUG).
Who is sponsoring clinical trial NCT07113522?
This trial is sponsored by Mirador Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07113522 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07113522's enrollment target sits among peer trials
140 59th of 105 higher than 46 of 105 other Crohn's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
RECRUITING · Phase 2
-
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI